Streetbeat News

FRLN

Freeline Therapeutics Holdings plc

https://www.freeline.life/

Employees

717

Industry

Biological Product (except Diagnostic) Manufacturing

freeline is a biopharmaceutical company focused on the development and commercialisation of gene therapies for bleeding and other debilitating disorders based on a next-generation aav gene therapy platform developed by amit nathwani, professor of haematology at ucl and cso of freeline therapeutics http://www.freelinetx.com

Open

6.49

Mkt cap

28M

Volume

5.3K

High

6.49

P/E Ratio

-0.57

52-wk high

8.74

Low

6.48

Div yield

N/A

52-wk low

2.11

Syncona has proposed to acquire all remaining shares of Freeline Therapeutics that it does not already own for $5.00 per ADS.

Portfolio Pulse from Charles Gross

October 18, 2023 | 10:15 am

Freeline Therapeutics will present new clinical data from its ongoing Phase 1/2 GALILEO-1 trial of FLT201 gene therapy candidate for Gaucher Disease Type 1 at the European Society of Gene & Cell Therapy Annual Congress.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2023 | 11:18 am

Several healthcare stocks experienced significant price movements during Monday's intraday session. Acurx Pharmaceuticals, Turnstone Biologics, Jin Medical International, ContraFect, Freeline Therapeutics, and RVL Pharmaceuticals saw their stock prices increase, while SeaStar Medical Holding, Addex Therapeutics, Etao International Co, Longeveron, Vaccinex, and Tango Therapeutics experienced declines.

Portfolio Pulse from Benzinga Insights

October 09, 2023 | 5:31 pm

Healthcare stocks showed significant movement in Friday's pre-market session. RVL Pharmaceuticals, Vaccinex, T2 Biosystems, Akso Health Group, Exagen, and Bone Biologics saw gains, while Freeline Therapeutics, Nanobiotix, Longeveron, Vivos Therapeutics, BioCardia, and Koninklijke Philips experienced losses.

Portfolio Pulse from Benzinga Insights

October 06, 2023 | 1:06 pm

During Thursday's after-market session, several health care stocks experienced significant movement. Vaccinex, Bone Biologics, Exagen, Vistagen Therapeutics, RVL Pharmaceuticals, and China Pharma Holding saw increases, while OKYO Pharma, Freeline Therapeutics, SomaLogic, Rallybio, Inhibikase Therapeutics, and YS Biopharma Co experienced decreases.

Portfolio Pulse from Benzinga Insights

October 05, 2023 | 9:32 pm

Freeline Therapeutics Holdings plc (NASDAQ:FRLN) reported initial data from its ongoing Phase 1/2 GALILEO-1 trial of FLT201, a gene therapy candidate for Gaucher disease. The data showed favorable safety and tolerability, with no serious adverse events. Both patients treated showed several hundred-fold increases in GCase activity, a key enzyme deficient in Gaucher disease. Following the news, FRLN shares are up 5.05%.

Portfolio Pulse from Vandana Singh

October 04, 2023 | 2:23 pm

In Wednesday's pre-market session, several healthcare stocks saw significant movement. Freeline Therapeutics, Vivos Therapeutics, Brainstorm Cell, Sonendo, Senti Biosciences, and Synlogic saw increases in their stock prices, while Kineta, Femasys, Alpha Teknova, Catheter Precision, Standard BioTools, and Addex Therapeutics experienced decreases.

Portfolio Pulse from Benzinga Insights

October 04, 2023 | 1:06 pm

Freeline reported positive initial clinical data from the first cohort of its Phase 1/2 GALILEO-1 trial of FLT201, a novel gene therapy candidate for Gaucher Disease. Inhibikase Therapeutics received FDA Orphan Drug Designation for Risvodetinib for the treatment of Multiple System Atrophy. Palantir Technologies collaborated with PwC to accelerate operational transformation.

Portfolio Pulse from ryanfaloona@benzinga.com

October 04, 2023 | 12:43 pm

Freeline Therapeutics has released initial data from the first cohort of its Phase 1/2 GALILEO-1 trial of FLT201 gene therapy for Gaucher disease. The positive results have led to an increase in the company's share price.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2023 | 12:36 pm

Freeline has reported positive initial clinical data from the first cohort of its Phase 1/2 GALILEO-1 trial of FLT201, a novel gene therapy candidate for Gaucher disease.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2023 | 11:02 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.